Industry Briefs: Mar. 5, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Galapagos has received EUR 3.5 million ($4.59 million) in milestone payments in its osteoarthritis alliance with Servier.
JHP Pharmaceuticals has added a second product to its previously announced multiyear contract manufacturing agreement with an undisclosed pharmaceutical company. JHP will be responsible for manufacturing and supply of an injectable anesthetic agent.
Lonza and Eclipse Therapeutics have formed a development and manufacturing agreement.
Mylan continues to pursue damages and and its injunction against Sunovion’s Brovana in an ongoing litigation. Mylan believes a federal district court erred in its partial summary judgment decision.
Pfenex and DNA2.0 have formed a collaboration on protein expression technology.
People News
Albany Molecular Research (AMRI) has named Tom McGrath as director of quality for aseptic services, and Chris Phillips has been appointed to the role of senior director of operations, at AMRI’s Burlington, Massachusetts site.
Alkermes has appointed Mark Stejbach as chief commercial officer.
AstraZeneca has announced the retirement of Louis Schweitzer from the board as chairman and as a director, effective Sept. 1, 2012.
Novartis has named Brian McNamara division head of Novartis OTC.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
